Baxter International Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Baxter International Inc.
With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
The deal gives Medtronic the exclusive right to acquire Half Moon Medical, a start-up developing a mitral valve repair system to compete with Abbott’s MitraClip.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Drug Delivery
- Infusion Therapy Equipment and Supplies
Surgical Equipment & Devices
- Surgical Sealants
- Other Names / Subsidiaries
- AesRX LLC
- Althin Medical A.B.
- Chatham Therapeutics
- Cheetah Medical
- Claris Injectables Limited
- Fusion Medical Technologies, Inc.
- Gambro AB
- Prism Pharmaceuticals, Inc.
- Renal Therapy Services
- SIGMA International Geneeral Medical Apparatus
- SuppreMol GmbH
- Synovis Life Technologies, Inc.
- Wound Care Technologies, Inc.
- Baxter Healthcare Corporation